<DOC>
	<DOCNO>NCT01458197</DOCNO>
	<brief_summary>1 . Primary Objective : To evaluate dose-response relationship tarafenacin efficacy . 2 . Secondary Objectives : - To compare 12 week ' efficacy different dos tarafenacin placebo patient suffer Overactive Bladder . . - To compare tolerability different dos tarafenacin placebo patient suffer Overactive Bladder . .</brief_summary>
	<brief_title>A Phase 2 Study Compare Efficacy Tolerability Tarafenacin 0.2 mg Tarafenacin 0.4 mg Placebo Patients Suffering From Overactive Bladder .</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>&lt; Inclusion Criteria &gt; 1 . Patient either sex age 20 80 year ( inclusive ) ; 2 . Patients suffer Overactive Bladder . base cardinal symptom ( urgency , nocturia , frequency without urge incontinence ) least 6 month prior inclusion ; 3 . Patients document follow symptom 3day diary card 14 day placebo runin period An average ≥8 micturitions/24 hour ; Greater equal three incontinence episodes A total ≥3 urgency episode . &lt; Exclusion Criteria &gt; 1 . Patients Clinically significant bladder outlet obstruction 2 . Patients predominant stress incontinence ( &gt; 2 episode/week ) 3 . Patients significant urogenital disease recurrent urinary tract infection ( 2/6 month ) , bladder calculus , interstitial cystitis , urothelial tumour , hysterectomy prostatectomy previous six month ; 4 . Females diagnose bladder cancer 5 . Males diagnose bladder cancer 6 . Patients obstructive disease gastrointestinal tract , intestinal inflammatory disease , severe ulcerative colitis , inflammatory bowel disease , toxic megacolon , intestinal atony paralytic ileum 7 . Patients acute Noehyeolgwangye disease , significant Cardiovascular Disease ( arrhythmia , unstable angina pectoris , myocardial infarct , use pacemaker ) , significant Orthostatic hypotension previous six month 8 . Patients diagnose closed angle glaucoma shallowness anterior chamber 9 . Patients contraindication antimuscarinic drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Tarafenacin</keyword>
</DOC>